BACKGROUND: For small children requiring mechanical circulatory support as a bridge to transplantation (BTT), extracorporeal membrane oxygenation (ECMO) has been the only option until the recent introduction of the Berlin Heart EXCOR ventricular assist device (Berlin Heart AG, Berlin, Germany). We reviewed our recent experience with these two technologies with particular focus on early outcomes. METHODS: Data for 55 consecutive children undergoing BTT between 2001 and 2008 were abstracted from an institutional database. The analysis excluded 13 patients because EXCOR was not used for acute postcardiotomy BTT. Patients were divided into ECMO (n = 21) and EXCOR groups (n = 21). Specific end points included survival to transplant, overall survival, and bridge to recovery. Incidences of adverse events and the duration of support were determined. RESULTS: Groups were similar in weight, age, and etiologies of heart failure. Likewise, the incidences of stroke and multisystem organ failure were similar. Survival to transplant, recovery, or continued support was 57% in ECMO and 86% in EXCOR (p = 0.040). EXCOR patients had overall significantly better survival (p = 0.049). Two ECMO patients and 1 EXOR patient were bridged to recovery. The mean duration of support was 15 +/- 12 days in the ECMO group and 42 +/- 43 days in the EXCOR group (p < 0.001). CONCLUSIONS: In children requiring BTT, EXCOR provided substantially longer support times than ECMO, without significant increase in the rates of stroke or multisystem organ failure. Survival to transplant and long-term survival was higher with EXCOR.
BACKGROUND: For small children requiring mechanical circulatory support as a bridge to transplantation (BTT), extracorporeal membrane oxygenation (ECMO) has been the only option until the recent introduction of the Berlin Heart EXCOR ventricular assist device (Berlin Heart AG, Berlin, Germany). We reviewed our recent experience with these two technologies with particular focus on early outcomes. METHODS: Data for 55 consecutive children undergoing BTT between 2001 and 2008 were abstracted from an institutional database. The analysis excluded 13 patients because EXCOR was not used for acute postcardiotomyBTT. Patients were divided into ECMO (n = 21) and EXCOR groups (n = 21). Specific end points included survival to transplant, overall survival, and bridge to recovery. Incidences of adverse events and the duration of support were determined. RESULTS: Groups were similar in weight, age, and etiologies of heart failure. Likewise, the incidences of stroke and multisystem organ failure were similar. Survival to transplant, recovery, or continued support was 57% in ECMO and 86% in EXCOR (p = 0.040). EXCOR patients had overall significantly better survival (p = 0.049). Two ECMO patients and 1 EXOR patient were bridged to recovery. The mean duration of support was 15 +/- 12 days in the ECMO group and 42 +/- 43 days in the EXCOR group (p < 0.001). CONCLUSIONS: In children requiring BTT, EXCOR provided substantially longer support times than ECMO, without significant increase in the rates of stroke or multisystem organ failure. Survival to transplant and long-term survival was higher with EXCOR.
Authors: Diego A Lara; Aamir Jeewa; Barbara A Elias; Elizabeth O McCullum; Susan W Denfield; William J Dreyer; Iki Adachi Journal: Tex Heart Inst J Date: 2017-02-01
Authors: William J Weiss; Elizabeth L Carney; J Brian Clark; Rebecca Peterson; Timothy K Cooper; Thomas P Nifong; Christopher A Siedlecki; Dennis Hicks; Bradley Doxtater; Branka Lukic; Eric Yeager; John Reibson; Joshua Cysyk; Gerson Rosenberg; William S Pierce Journal: ASAIO J Date: 2012 Jan-Feb Impact factor: 2.872
Authors: D Bradford Sanders; Steven R Sowell; Brigham Willis; John Lane; Christopher Pierce; Stephen Pophal; Francisco A Arabia; John J Nigro Journal: J Extra Corpor Technol Date: 2012-12
Authors: Carlo R Bartoli; Steven C Koenig; Constantine Ionan; Kevin J Gillars; Mike E Mitchell; Erle H Austin; Laman A Gray; George M Pantalos Journal: Pediatr Crit Care Med Date: 2013-11 Impact factor: 3.624